Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased...
2019年7月8日 · An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.
License pact for L606, potential long-acting version of Tyvaso...
2024年10月9日 · Approved treatments for people with PH-ILD lacking in many countries. In a previous Phase 1 study (NCT04041648) assessing L606’s pharmacokinetics — its movement into, through, and out of the body — in healthy adults, the treatment showed therapeutic levels for up to 12 hours, with a blood plasma peak concentration seven times lower than Tyvaso, the company reported.
For PAH Treatment, Mylan Launches Tadalafil Tablets, 1st Generic...
2018年8月22日 · “Mylan has a strong history of leading the way in creating important access to generic medicines, and we’re excited to continue that tradition by offering the first generic to Adcirca Tablets,” Heather Bresch, CEO of Mylan, said in a press release.. “Mylan offers more than 650 products in the U.S., and the addition of Tadalafil Tablets strengthens our …
Winrevair 'overwhelming' at treating advanced PAH in Phase 3 trial
2024年11月27日 · These top-line findings in the ongoing ZENITH trial (NCT04896008), testing the Merck treatment against a placebo while on background therapy, led an independent data monitoring committee to recommend the trial be stopped early. All enrolled patients now are invited to enter the open-label SOTERIA (NCT04796337) extension study and be …
Study IDs possible markers of PAH prognosis, treatment response
2024年12月11日 · Levels of D-dimer, a marker of blood clot formation, were also increased in PAH patients, the study found. This added to an increased risk of worse outcomes — such as a need for lung transplant or hospitalization — when angiopoietin-2 levels were high.
Taking selenium supplements may help prevent PAH: Study
2024年10月7日 · Investigating the role of selenium in people with PAH. PAH is a type of pulmonary hypertension (PH) caused by the narrowing of the pulmonary arteries, which are the blood vessels that supply the lungs. This leads to high blood pressure and may cause right heart failure, the most common cause of death among PAH patients.
MicroRNA in blood could be PAH marker in congenital heart disease
2024年11月22日 · The study, “ Expression and Diagnostic Value of miR-3591-5p in Patients with Congenital Heart Disease-Associated Pulmonary Arterial Hypertension,” was published in Lung. PAH is marked by high blood pressure in the vessels that carry blood through the lungs. People with congenital heart disease (CHD), a broad category that encompasses problems with heart structure or function from birth ...
FDA approves sotatercept, now Winrevair, to treat PAH in adults
2024年3月27日 · The now-approved treatment is expected to be available for dispensing by select U.S. specialty pharmacies by the end of April, according to Merck, which has owned the rights to the biologic therapy since acquiring prior developer Acceleron Pharma in 2021. Winrevair specifically is intended to enhance exercise capacity, improve World Health Organization (WHO) functional class, and reduce the ...
Different Uptravi maintenance doses led to similar outcomes: Study
2024年9月25日 · Investigating patient outcomes with varying Uptravi maintenance doses. Uptravi is approved for adults with PAH, a condition marked by high blood pressure caused by the narrowing of blood vessels that transport blood through the lungs.
Including Uptravi early in PAH treatment lowers hospitalization risk
2024年11月8日 · The study, “ Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension,” was published in JAMA Network Open.The work was funded by Actelion Pharmaceuticals, a part of Johnson & Johnson, which sells Uptravi.. PAH is marked by increased blood pressure in the vessels of the lungs, which puts strain on the heart.